Aprea Therapeutics (NASDAQ:APRE) Given Buy Rating at HC Wainwright
HC Wainwright reissued their buy rating on shares of Aprea Therapeutics (NASDAQ:APRE – Free Report) in a research report sent to investors on Monday, Benzinga reports. They currently have a $20.00 target price on the stock. Separately, Wedbush restated an outperform rating and issued a $11.00 price target on shares of Aprea Therapeutics in a […]
More Stories
Will Japanese Series, The Fragrant Flower Blooms With Dignity, Return for Season 2?
The Japanese animated drama, The Fragrant Flower Blooms With Dignity, is getting praised by many viewers from around the world....
6 Best Analytics Agencies in 2026 to Level Up Your Data Strategy
What do businesses do? Build and innovate from raw and scratch, right? But creation generates its own new raw material,...
Dalton Gomez Net Worth: How Rich Is Ariana Grande’s Ex-Husband?
He became popular following his affair with Ariana Grande. Even before he got into a relationship with Ariana, he was...
Trump Admin Aims to Create Family-Friendly Airports With Healthier Foods, Exercise Areas
By Jill McLaughlin The Trump administration is ready to spend $1 billion to create healthier food options, private breastfeeding pods,...
Trump Tells Xi US Will Ship Nvidia H200 Chips to ‘Approved Customers’ in China
By Catherine Yang President Donald Trump announced on Truth Social on Dec. 8 that he told Chinese Communist Party (CCP)...
Trump Announces $12 Billion Farm Aid Program
By Jacob Burg President Donald Trump on Dec. 8 unveiled a $12 billion economic assistance package for farmers. The Trump...